Key points are not available for this paper at this time.
Belantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent in combination with standard-care therapies.
Building similarity graph...
Analyzing shared references across papers
Loading...
Vânia Hungria
Paweł Robak
Marek Hus
New England Journal of Medicine
Universidade de São Paulo
Soochow University
Centro de Investigación del Cáncer
Building similarity graph...
Analyzing shared references across papers
Loading...
Hungria et al. (Sat,) studied this question.
www.synapsesocial.com/papers/68e669a9b6db6435875f575e — DOI: https://doi.org/10.1056/nejmoa2405090
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: